Polyrizon (NASDAQ:PLRZ) Downgraded by Wall Street Zen to Sell

Wall Street Zen lowered shares of Polyrizon (NASDAQ:PLRZ) from a hold rating to a sell rating in a report released on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings cut Polyrizon from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 1st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Polyrizon Price Performance

PLRZ stock opened at $11.03 on Friday. The stock’s fifty day simple moving average is $12.25 and its two-hundred day simple moving average is $13.00. Polyrizon has a 1-year low of $2.88 and a 1-year high of $18.20.

Institutional Trading of Polyrizon

A hedge fund recently bought a new position in Polyrizon stock. Jane Street Group LLC purchased a new position in shares of Polyrizon Ltd. (NASDAQ:PLRZ) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned 1.35% of Polyrizon as of its most recent filing with the SEC.

Polyrizon Company Profile

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.